ALBT

Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.

Wall Street analysts forecast ALBT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALBT is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Avalon Globocare Corp revenue for the last quarter amounts to 350.10K USD, increased 1.43 % YoY.

Avalon Globocare Corp. EPS for the last quarter amounts to -0.06 USD, decreased -96.70 % YoY.

Avalon Globocare Corp (ALBT) has 5 emplpoyees as of December 15 2025.

Today ALBT has the market capitalization of 5.70M USD.